IQVIA (NYSE:IQV) Raised to “Buy” at StockNews.com

IQVIA (NYSE:IQV) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday.

Other research analysts have also recently issued research reports about the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Morgan Stanley dropped their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. BTIG Research lowered their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Truist Financial cut their price objective on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Price Performance

NYSE:IQV opened at $197.57 on Wednesday. IQVIA has a 52 week low of $187.62 and a 52 week high of $261.73. The stock’s fifty day moving average is $223.40 and its two-hundred day moving average is $227.35. The company has a market capitalization of $35.86 billion, a P/E ratio of 25.93, a P/E/G ratio of 1.97 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of IQVIA

A number of institutional investors have recently bought and sold shares of IQV. Unigestion Holding SA purchased a new position in shares of IQVIA in the 3rd quarter valued at about $521,000. TD Private Client Wealth LLC increased its stake in IQVIA by 8.4% in the third quarter. TD Private Client Wealth LLC now owns 1,031 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 80 shares during the last quarter. Toronto Dominion Bank raised its holdings in IQVIA by 11.3% during the third quarter. Toronto Dominion Bank now owns 60,416 shares of the medical research company’s stock worth $14,317,000 after purchasing an additional 6,149 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of IQVIA during the 3rd quarter worth approximately $470,000. Finally, Brown Financial Advisors boosted its holdings in shares of IQVIA by 13.0% in the 3rd quarter. Brown Financial Advisors now owns 3,432 shares of the medical research company’s stock valued at $813,000 after buying an additional 396 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.